Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

Johnson & JohnsonJNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

This week's dividend activity included increased payouts from Citigroup (NYSE:C) and Duke Energy (DUK) as well as ...

Johnson & Johnson sought help from its three rival Covid-19 vaccine makers to look into reports of blood clots, but Pfizer and Moderna both declined, the Wall Street Journal reported on Friday ...

Pfizer and Johnson & Johnson are two healthcare giants. Both have a solid earnings growth outlook, but they differ in terms of valuation, as well as in the dividend yields they offer right here.

Some consumers have been wary of the Johnson & Johnson vaccine because its overall efficacy in clinical trials was 66% compared with about 95% for the Moderna and Pfizer vaccines.

Johnson & Johnson expects to make $2.5 billion in revenue from its COVID-19 vaccine in 2021. That's a drop in the bucket for the mammoth business, which generated more than $80 billion in revenue ...

The Pfizer vaccine is the first to receive FDA approval, while the Moderna and Johnson & Johnson vaccines are available under an emergency use authorization. For children ages 12 to 15 , Pfizer's ...